DAWNRAYS PHARMACEUTICAL (HOLDINGS) LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.17 HKD | -1.68% |
|
-2.50% | +11.43% |
| Mar. 26 | Dawnrays Pharmaceutical Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 12 June 2024 | CI |
| Mar. 25 | Dawnrays' 2023 Profit Falls 9% on Lower Revenue | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Dawnrays Pharmaceutical (Holdings) Limited is an investment holding company principally engaged in the development, manufacture and sale of non-patented pharmaceutical medicines. The products include intermediate pharmaceutical, bulk medicines and finished drugs. The Company operates its business through two segments. The Intermediates and Bulk Medicines segment is engaged in the manufacture and sale of intermediates and bulk medicines. The Finished Drugs segment is engaged in the manufacture and sale of finished drugs, including antibiotics finished drugs and non-antibiotics finished drugs.
Sector
Pharmaceuticals
Calendar
2024-05-27
- Final dividend
| 1st Jan change | Capi. | |
|---|---|---|
| +11.43% | 228M | |
| +25.61% | 672B | |
| +25.87% | 570B | |
| -5.24% | 360B | |
| +16.49% | 321B | |
| +8.28% | 300B | |
| +7.09% | 217B | |
| -9.12% | 204B | |
| +5.01% | 199B | |
| -8.75% | 149B |
- Stock Market
- Equities
- 2348 Stock
- News Dawnrays Pharmaceutical (Holdings) Limited
- Dawnrays Pharmaceutical : , Akeso Raise Joint Venture Capital, Start Phase Three Clinical Trial of Therapeutic Antibody
